ÂÜÀòÂÒÂ×

With more than two decades of experience helping shepherd promising new drugs through development, Dr. Proniuk remembers what first drew him to the high-risk, high-reward world of global drug development. He found it quite interesting because it is so cross-disciplinary—it involves material sciences, biology, medicine, and working with some of the top clinicians in the world. Every day, it is something different, and the caliber of people he has the opportunity to deal with on a regular basis makes it so interesting.

During his tenure as a chief development officer at New Jersey-based Arno Therapeutics, he became particularly interested in oncology drug development.

His interest to develop novel oncology therapies motivated Dr. Proniuk to lend his expertise to drug investigators like Genzada—helping them navigate the scientific rigors and scope of drug development from technical operations and clinical trials to regulatory guidance and the scale-up and launch of next-generation dosage forms.

Over the course of his career, Dr. Proniuk has held leadership positions at Neuraptive, Arno Therapeutics, Neurocrine Bioscience, and Cima Labs. He holds a Ph.D. in Pharmaceutical Sciences from the University of Arizona, an MBA in Entrepreneurship from San Diego State University, and a Diplom (FH) in Chemical Engineering from the University of Applied Sciences Isny, Germany.